Biohaven Pharmaceutical Holding Co Ltd

Biohaven Pharmaceutical Holding Company Ltd. is a biopharmaceutical company that develops product candidates to treat neurological diseases and rare disorders. Operating in the United States and incorporated in 2013, Biohaven Pharmaceutical has its headquarters in New Haven, Connecticut. As of November 2021, Biohaven Pharmaceutical has a range of product candidates that are undergoing clinical testing, in addition to one product that has received approval for treatment in the United States. NURTEC ODT (rimegepant) has been approved for the acute treatment of migraines as well as for preventative treatment of migraines. Zavegepant is currently in phase III clinical trials for acute and preventative treatment of migraines, in addition to being tested for treatment of respiratory complications of Covid-19. The company also has Troriluzole in phase III clinical trials for the treatment of spinocerebellar ataxia (SCA) and obsessive-compulsive disorders (OCD). Verdiperstat is in phase III clinical trials for treating amyotrophic lateral sclerosis (ALS). Biohaven Pharmaceutical stock is listed on the NYSE under the ticker BHVN. The company has a collaborative agreement with Cove to facilitate telemedicine evaluation for those who suffer from migraines. In January 2021, Biohaven Pharmaceutical announced that it had acquired the remaining interest in Kleo Pharmaceuticals that it did not previously own. Keep an eye on the price movements of BHVN stock by adding it to your eToro watchlist.